Literature DB >> 16227761

Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.

George L Bakris1, David Hg Smith, Thomas D Giles, William B White, Giora Davidai, Michael A Weber.   

Abstract

Blood pressure (BP) reductions with agents that block the renin-angiotensin system are regarded as less effective as monotherapy in African Americans than other ethnic groups. This practice-based study compares the efficacy of an angiotensin receptor blocker-based regimen in African-American and Caucasian patients. Included in the 10-week study were 173 African-American and 1296 Caucasian patients. Efficacy was based on differences in 24-hour ambulatory BP. After baseline ambulatory BP monitoring and office BPs were obtained, all patients were started or switched to the angiotensin receptor blocker telmisartan, 40-80 mg daily, plus hydrochlorothiazide 12.5 mg daily (if needed for office BP control: <140/90 mm Hg). More African Americans required the addition of a low-dose thiazide diuretic than Caucasians (47.3% vs. 34.9%; p=0.021). Once patients with white coat hypertension were excluded (i.e., those with baseline ambulatory BP monitoring <130/80 mm Hg), ambulatory BP monitoring changes were similar between groups. A greater proportion of African Americans than Caucasians without white coat hypertension also needed combination therapy (52.1% vs. 39.5%; p=0.04). While achievement of BP goal was similar between groups by office criterion (<140/90 mm Hg), differences were noted by ambulatory BP monitoring (<130/80 mm Hg) (48.0% in African American vs. 63.2% in Caucasians; p=0.01) despite the same BP reductions, reflecting higher baseline values in African Americans. We conclude that an angiotensin receptor blocker as part of a BP-lowering strategy is effective in previously untreated African-American patients, although a higher proportion will require the use of a diuretic compared with Caucasians.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227761      PMCID: PMC8109501          DOI: 10.1111/j.1524-6175.2005.04666.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  19 in total

1.  Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks.

Authors:  Janice G Douglas; George L Bakris; Murray Epstein; Keith C Ferdinand; Carlos Ferrario; John M Flack; Kenneth A Jamerson; Wendell E Jones; Julian Haywood; Randall Maxey; Elizabeth O Ofili; Elijah Saunders; Ernesto L Schiffrin; Domenic A Sica; James R Sowers; Donald G Vidt
Journal:  Arch Intern Med       Date:  2003-03-10

2.  External validity of randomised controlled trials: "to whom do the results of this trial apply?".

Authors:  Peter M Rothwell
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

3.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

4.  Human blood pressure determination by sphygmomanometry.

Authors:  D Perloff; C Grim; J Flack; E D Frohlich; M Hill; M McDonald; B Z Morgenstern
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.

Authors:  Michael A Weber; Stevo Julius; Sverre E Kjeldsen; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John H Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; M Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

7.  Blood pressure effects of the angiotensin II receptor blocker, losartan.

Authors:  M A Weber; R L Byyny; J H Pratt; E P Faison; D B Snavely; A I Goldberg; E B Nelson
Journal:  Arch Intern Med       Date:  1995-02-27

8.  Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  B J Materson; D J Reda; W C Cushman; B M Massie; E D Freis; M S Kochar; R J Hamburger; C Fye; R Lakshman; J Gottdiener
Journal:  N Engl J Med       Date:  1993-04-01       Impact factor: 91.245

9.  Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.

Authors:  William B White; Yves Lacourciere; Giora Davidai
Journal:  Am J Hypertens       Date:  2004-04       Impact factor: 2.689

10.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

View more
  6 in total

1.  Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.

Authors:  Elizabeth O Ofili; Dion H Zappe; Das Purkayastha; Rita Samuel; James R Sowers
Journal:  Am J Ther       Date:  2013-01       Impact factor: 2.688

2.  Impaired relaxation of cerebral arteries in the absence of elevated salt intake in normotensive congenic rats carrying the Dahl salt-sensitive renin gene.

Authors:  Matthew J Durand; Carol Moreno; Andrew S Greene; Julian H Lombard
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-17       Impact factor: 4.733

Review 3.  Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension.

Authors:  Greg L Plosker; William B White
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Angiotensin receptor blockers: pharmacology, efficacy, and safety.

Authors:  Addison A Taylor; Helmy Siragy; Shawna Nesbitt
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-27       Impact factor: 3.738

5.  Direct renin inhibition--commonly asked questions.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-11       Impact factor: 3.738

6.  Blood pressure effects of high-dose amlodipine-benazepril combination in Black and White hypertensive patients not controlled on monotherapy.

Authors:  Steven G Chrysant
Journal:  Drugs R D       Date:  2012-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.